SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on August 26, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart. The awards consisted of stock options to purchase an aggregate of 21,500 shares of Vaxart's common stock, which vest as to ...

Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines. The analyst's bullish view is centered around optimism associated with attractive opportunities for Vaxart's 'differentiated' oral vaccine platform and key programs, such as the norovirus vaccine and COVID-19 vaccine. Oppenheimer initiated with an Outperform rating and a price target of $4, representing significant potential upside. ...

Vaxart, Inc. (NASDAQ:VXRT) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ed Berg - SVP & General Counsel Steven Lo - CEO Sean Tucker - Founder & Chief Scientific Officer James Cummings - Chief Medical Officer Phil Lee - CFO Conference Call Participants Elaine Kim - Cantor Fitzgerald Operator Greetings and welcome to the Vaxart Business Update and Second Quarter 2024 financial results, conference call, a question and answer session will follow management's opening remarks. I ...

VAXART, INC. (VXRT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -400%. A quarter ago, it was expected that this company would post a loss of $0.16 per share when it actually produced a loss of $0.14, delivering a surprise of 12.50%. Over the last four quarters, the company has surpassed consensus ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35285 Vaxart, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 59-1212264 (State or other ...

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results Exhibit 99.1 BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart's oral pill vaccine platform as a nextgeneration approach to combating COVID-19 and future pandemic threats Solid financial position enables Vaxart to execute on multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 8, 2024 — Vaxart, Inc. (Nasdaq: VXRT) today annou ...

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursday, August 8, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click here Date: Thurs ...

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursday, August 8, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click here Date: Thurs ...

Vaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Ed Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer Sean Tucker - Founder and Chief Scientific Officer James Cummings - Chief Medical Officer Phil Lee - Chief Financial Officer Conference Call Participants Madison Britt Wynne El-Saadi - B. Riley Securities Aseah Khan - Cantor Fitzgerald Liang Cheng - Jefferies Operator Greetings, and welcome to the Vaxart Business Upda ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such re ...